<DOC>
	<DOCNO>NCT01455675</DOCNO>
	<brief_summary>The purpose study prolong time reinfection Pseudomonas aeruginosa successfully treat acute intermittent infection .</brief_summary>
	<brief_title>Efficacy Study IgY ( Antibody Against Pseudomonas ) Cystic Fibrosis Patients</brief_title>
	<detailed_description>This double -blind , placebo control study investigational drug reference placebo group gargle swallow . 70 ml IgY/ placebo solution gargle every night two minute ( maximal 24 month ) The design include recruitment 144 patient randomize two group ( 72 per treatment group ) In order compensate dropout ( i.e . patient drop prior 24 month without event ) total sample size plan approximately 180 ( i.e . ~20 % dropout rate ) . After actual drop-out rate low throughout study , 144 plus approx . 10 % potential drop-outs include study . During two year treatment , subject examine clinic every 3 month regard safety efficacy medication . For information please see www.impactt.eu The IMPACTT Project fund EU within Framework 7 Program . PsAer-IgY Studies part IMPACTT Project ( Workpackage 2 ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>CF patient diagnose accord specific clinical feature either positive sweat chloride double proof presence diseaseassociated CFTR mutation alleles Males females 5 year age ( able gargle ) CF patient FEV1 value 50 % 130 % predict value ( accord Knudson formula ) CF patient one several sputum throat cough swab endolaryngeal suction culture positive PA within last three year PA successfully eradicate . Sputum / throat cough swab/ endolaryngeal suction culture negative PA gramnegative bacteria study entry . Patients and/ legal representative willing able give inform consent/ assent participate study thorough information Subjects child bear potential sexually active must meet contraception requirement ( i.e . oral injectable contraceptive , intrauterine device , doublebarrier method , contraceptive patch , male partner sterilization condom ) . Microbiologic serologic evidence chronic infection PA . Definition chronic PA infection : Three culture ( sputum throat cough swab endolaryngeal suction ) positive PA 6 consecutive month ( least 3 culture take ) , . Patients , positive sputum culture throat cough swab endolaryngeal suction culture gramnegative bacteria , PA , S. maltophilia , B. cepacia , A. xylosoxidans ( eradication entry study possible ) , Patients , positive sputum culture throat cough swab endolaryngeal suction culture atypical Mycobacteria / Aspergillus fumigates , associate clinical symptom may necessitate specific treatment . History allergy/hypersensitivity hen ' egg protein ( include medication allergy ) deem relevant trial investigator . `` Relevance '' context refers increase risk hypersensitivity reaction trial medication . Patient know relevant substance abuse , include alcohol drug abuse . Start new concomitant chronic medication CF within 4 week inclusion . Clinically relevant diseases medical condition CF CFrelated condition , opinion investigator , would compromise safety patient quality data . This include , limited , significant hematological , hepatic , renal , cardiovascular , neurological disease ( diabetic patient may participate disease good control prior inclusion ) . Participation another study investigational drug within one month 6 halflives ( whichever great ) precede inclusion . The patient employee investigator institution direct involvement trial trial direction investigator member . Patients pregnant include study . This tested inclusion visit urine pregnancy test ( female patient older 10 year secondary sexual characteristic )</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>cystic fibrosis</keyword>
</DOC>